Lymphoma: all 5,624 studies

Page 34 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha InterferonCompletedNCT03069248Phase 2
• Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on LenalidomideTerminatedNCT03065790
• Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT03064867Phase 1/2
• The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular FunctionCompletedNCT03062878
• Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic PatientsStatus unknownNCT03062072
• Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid TumorsTerminatedNCT03061305
• A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownNCT03060850Phase 1
• Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AuriхimCompletedNCT03057418Phase 1
• Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose TherapyCompletedNCT03054883
• Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell LymphomaStatus unknownNCT03054532Phase 2
• Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese ParticipantsCompletedNCT03053024
• Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer SurvivorsCompletedNCT03052777Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell LymphomaStatus unknownNCT03051581Not applicable
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell LymphomaStatus unknownNCT03051568Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051555Not applicable
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051542Not applicable
• The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B LymphomaStatus unknownNCT03045471
• PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Phase 1/2
• Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHLCompletedNCT03042585Not applicable
• Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin LymphomaStatus unknownNCT03042247
• Risk Stratification of Nodal PTCLCompletedNCT03040206
• Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
• Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
• Mediastinal Grey Zone Lymphoma From the LYSACompletedNCT03037177
• Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasCompletedNCT03036904Phase 1
• CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaCompletedNCT03029338Phase 1
• Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma PatientsStatus unknownNCT03023358Phase 3
• The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell LymphomaStatus unknownNCT03022123Not applicable
• Pembrolizumab for T/NK-cell lymphomasNK-cell LymphomasStatus unknownNCT03021057Phase 2
• Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
• R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCLStatus unknownNCT03018626Phase 3
• The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell LymphomaStatus unknownNCT03016988Phase 2
• Thalidomide Maintenance Treatment in DLBCLStatus unknownNCT03016000Phase 3
• Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT03013933Phase 1
• Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1
• Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT03010579Phase 4
• Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2
• Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialCompletedNCT03003546Phase 1
• A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaCompletedNCT03003039Phase 1
• The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
• HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeStatus unknownNCT03000192
• Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
• PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent NeutropeniaStatus unknownNCT02996617Phase 4
• Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell LymphomaStatus unknownNCT02992834Phase 4
• Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
• Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCTCompletedNCT02992223
• Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
• Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCLCompletedNCT02987400Phase 2
• Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell LymphomaStatus unknownNCT02987244Phase 1/2
• Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT LymphomaStatus unknownNCT02987127
• Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System LymphomaStatus unknownNCT02983942Phase 1/2
• Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
• Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
• CD180 Overexpression in Follicular LymphomaCompletedNCT02978898
• A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaTerminatedNCT02978235Phase 1
• A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsCompletedNCT02976857Phase 1
• Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
• Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial ChemoimmunotherapyTerminatedNCT02966730Early Phase 1
• Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ LymphomaStatus unknownNCT02965157Phase 1/2
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma PatientsCompletedNCT02963389Phase 1
• Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed LymphomaWithdrawnNCT02961816Phase 2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT02957019Phase 1/2
• A Phase II Study of the FIL on Elderly Frail Patients With DLBCLCompletedNCT02955823Phase 2
• RICE-ibrutinib in Relapsed DLBCLStatus unknownNCT02955628Phase 2
• Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant RecoveryCompletedNCT02955043Not applicable
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
• Causes of Death in Follicular Lymphoma: a Single Center Retrospective AnalysisCompletedNCT02951871
• Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
• Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
• Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone LymphomaCompletedNCT02945319
• A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Phase 1
• Chidamide for Refractory/Relapsed Peripheral T Cell LymphomaStatus unknownNCT02944812Phase 2
• ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell TumorsStatus unknownNCT02938741Phase 4
• APG-115 in Patients With Advanced Solid Tumors or LymphomasCompletedNCT02935907Phase 1
• Whole Body PET-MRI in Paediatric and Adolescent LymphomaStatus unknownNCT02935348
• Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19Active, not recruitingNCT02935257Phase 1
• Temozolomide in Treatment of Patients With Primary Central Nervous System LymphomaStatus unknownNCT02934204Phase 2
• CD19-redirected Autologous Cells (CAR-CD19 T Cells)Status unknownNCT02933775Phase 1
• Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingNCT02932280Phase 1/2
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02931201Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02928861Not applicable
• Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
• Italian Multicenter Retrospective Observational Study on Transformed LymphomasStatus unknownNCT02927756
• An Italian Experience on Grade 3b Follicular LymphomaStatus unknownNCT02927717
• Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedNCT02924402Phase 1
• PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early StageStatus unknownNCT02918747Phase 2
• Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
• Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-CellCompletedNCT02916316
• A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
• Thiopurine EnhAnced Maintenance TherapyCompletedNCT02912676Phase 1/2
• Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCompletedNCT02909777Phase 1
• PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT02905942Phase 4
• Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
• Occupational Exposure to Pesticides in the Prognosis of LymphomasTerminatedNCT02898870
• PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
• Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasCompletedNCT02891590Phase 1
• Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
• Erythropoietin for Management of Anemia Caused by ChemotherapyCompletedNCT02890602Phase 2
• Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyActive, not recruitingNCT02889523Phase 1/2

← Lymphoma overview